Aurora Spine, Inc., a firm specializing in minimally-invasive regenerative technologies, has named Richard Moss vice president of International Business Development. Since February 2009, Moss was vice president of International Sales at Doctors Research Group. He also served as director of sales (Europe) for TranS1, Inc, a publically traded company based in Wilmington, North Carolina.
Richard Moss Joins Aurora Spine
1 min read Premium comments
Moss’ past experience also includes a stint as international sales and marketing manager at Atlantech Medical Devices, Ltd, located at Harrogate, United Kingdom. He later served as director of sales emea sports medicine for the ArthroCare Corporation based in Austin, Texas.
“I am thrilled to join Aurora; I see the ZIP ISP fusion device and pipeline of product developments helping to change the way spine surgeons fundamentally treat their patients, ” Moss said, adding that he specializes in international sales and distribution management.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.